Clinical trials
Leukemia Acute Myeloid - AML clinical trials
Below are recruiting leukemia acute myeloid - aml clinical trials, each written for real people, not researchers. We’re tracking 100 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06279572Recruiting
Immune study of azacitidine and venetoclax in first AML treatment
This study looks at the immune system of adults with newly diagnosed AML who receive their first treatment of azacitidine and venetoclax. Researchers want to understand how this chemotherapy affects your immune cells.
Scottsdale, ArizonaAges 18 years+ - NCT06297551Recruiting
Study of leukemia stem cell markers in AML
This trial looks at two markers, CLL1 and CD45RA, found on some leukemia cells. It aims to help doctors better understand and treat acute myeloid leukemia (AML) by measuring these markers at diagnosis.
Stony Brook, New YorkAges 18 years+ - NCT06299462RecruitingPhase 1/Phase 2
Preventing GVHD with PTCy and ATG in stem cell transplant
This trial tests a combination of two drugs (PTCy and ATG) to prevent graft-versus-host disease after a stem cell transplant from a matched donor. It is for adults with certain blood cancers who are between 18 and 60 and have a suitable donor.
Rio de Janeiro, Rio de JaneiroAges 18–60 - NCT06382168RecruitingPhase 1/Phase 2
DFP-10917 plus venetoclax for AML that has returned or not improved
This trial tests a new combination of two drugs, DFP-10917 and venetoclax, for people with AML that has returned or not improved after previous treatments. The goal is to see if this combination can help control the leukemia.
Orange, CaliforniaAges 18 years+ - NCT06409936RecruitingPhase 2
Early use of asciminib for new CML patients
This trial tests the drug asciminib for people newly diagnosed with chronic myeloid leukemia (CML) who have been on treatment for less than a month. It aims to see if early treatment with asciminib is safe and effective.
BarcelonaAges 18 years+ - NCT06477549RecruitingPhase 2
Comparing Two Drug Combinations for Stem Cell Transplant
This study compares two different drug combinations (BeFluBu and FluBuRux) used before a stem cell transplant from a half-matched (haploidentical) donor. The goal is to see which combination works better to prepare your body for the transplant and control your blood cancer.
Saint PetersburgAges 18–75 - NCT06508099RecruitingPhase 2
Vitamin A and D supplements after stem cell transplant
This trial tests whether taking vitamin A and D after a stem cell transplant can help improve recovery. It is for people with certain blood cancers who have a matched donor and are in remission or have low disease activity.
Saint PetersburgAges 18 years+ - NCT06532084RecruitingPhase 2
Sorafenib to prevent relapse after stem cell transplant
This trial tests whether the drug sorafenib can prevent blood cancer from returning after a stem cell transplant. It is for people who had a special combination of chemotherapy (bendamustine and cyclophosphamide) during their transplant and are at high risk for relapse.
Saint PetersburgAges 18–75 - NCT06535113Recruiting
Inflammation and treatment response in AML
This study looks at how inflammation (the body's response to injury or infection) affects treatment outcomes in people with acute myeloid leukemia (AML). If you have a new diagnosis or have stored samples from a past diagnosis, you may help researchers understand why some people respond better to therapy.
Reggio Calabria, CalabriaAges 18 years+ - NCT06551584RecruitingPhase 1
Advanced blood cancer trial with stem cell transplant
This trial tests a new approach for people with advanced blood cancers who are getting a donor stem cell transplant. It aims to improve outcomes by using your own regulatory T cells along with the donor cells.
Palo Alto, CaliforniaAges 18–70 - NCT06599762RecruitingPhase 2
Tranexamic acid for bleeding in MDS and AML
This trial tests if tranexamic acid, a medicine that helps blood clot, can reduce bleeding in people with myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML) who have very low platelet counts and are receiving less-intensive chemotherapy.
Winnipeg, ManitobaAges 18 years+ - NCT03810196Recruiting
Stem cell addback after transplant to treat viral or fungal infection
This study tests a stem cell “addback” treatment after a specific type of transplant (with certain immune cells removed). It may help the body recover faster and fight serious viral or fungal infections in children and teens.
Philadelphia, PennsylvaniaAges Up to 25 years - NCT07020533RecruitingPhase 1
CMV vaccine for stem cell transplant recipients
This trial tests a vaccine designed to boost immunity against CMV (a common virus) and prevent active CMV infection in people receiving a half-matched stem cell transplant. It may help protect you from CMV-related complications after transplant.
Duarte, CaliforniaAges 18–75 - NCT07216443RecruitingPhase 2
Study of orca-t for leukemia or MDS with reduced intensity chemo
This trial tests a new cell therapy, orca-t, given after a lower-intensity chemo and radiation regimen for people with acute myeloid leukemia, mixed phenotype leukemia, or myelodysplastic syndrome. It aims to help patients who cannot tolerate full-intensity transplant conditioning.
Los Angeles, CaliforniaAges 18 years+ - NCT06764459Recruiting
Study of FLT3 gene changes in AML patients
This trial looks at people with acute myeloid leukemia (AML) who have a change in a gene called FLT3. It aims to understand how this change affects the disease and how well treatments work.
BolognaAges 18 years+ - NCT06785077Recruiting
Genetic Study in Ovarian Cancer During PARP Inhibitor Therapy
This study looks at the genetic changes in ovarian cancer cells before and during treatment with PARP inhibitors. It aims to understand how these changes may affect treatment response.
MilanAges 18 years+ - NCT06839456RecruitingPhase 1/Phase 2
Stem cell addback to prevent infections after transplant
This trial tests whether adding back certain immune cells after a stem cell transplant can help prevent serious viral or fungal infections. It's for children and young adults up to age 25 who need a transplant for a blood cancer or other curable disease.
Philadelphia, PennsylvaniaAges 1 month–25 years - NCT06882057RecruitingPhase 2/Phase 3
Treatment for newly diagnosed low-risk pediatric B-ALL
This trial tests a treatment plan for children newly diagnosed with low-risk B-cell ALL. It aims to improve outcomes while reducing side effects.
Hefei, AnhuiAges 1–18 - NCT06956755Recruiting
Registry for MDS and treatment-related leukemia
This study collects information from people with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) that developed after cancer treatment. It does not test a new drug but helps doctors learn more about these conditions.
RouenAges 18 years+ - NCT07012447RecruitingPhase 2
Venetoclax with azacytidine for newly diagnosed T-cell leukemia
This trial tests a combination of venetoclax and azacytidine for people with certain types of T-cell acute lymphoblastic leukemia (T-ALL) that haven't been treated yet. It focuses on cases with specific genetic changes and aims to see if this drug pair can help control the disease.
Suzhou, JiangsuAges 14 years+ - NCT07256210RecruitingPhase 2
Donor NK cells to prevent leukemia return after stem cell transplant
This trial tests whether giving donor natural killer (NK) cells after a stem cell transplant can help prevent leukemia from coming back. It is for people aged 14-25 with certain hard-to-treat leukemias who are already getting a stem cell transplant from a related donor.
MoscowAges 1 month–25 years - NCT03802695RecruitingPhase 1
Orca-Q pill to help during stem cell transplant
This Phase 1 trial studies Orca-Q to see if it is safe and works when added around the time of an allogeneic (donor) stem cell transplant for certain blood cancers. If you qualify, the study may offer a new option for managing the transplant immune response.
Duarte, CaliforniaAges 12–78 - NCT07366801RecruitingPhase 2/Phase 3
Preventing graft versus host disease in children with blood cancer
This trial tests if adding special immune cells (Treg cells) to a stem cell transplant from a half-matched donor can lower the risk of graft versus host disease (a serious side effect where donor cells attack the patient's body) in children and young adults with blood cancers.
MoscowAges 1–25 - NCT03222674RecruitingPhase 1/Phase 2
CAR T treatment for acute myeloid leukemia in children and adults
This trial tests a lab-made immune cell treatment (CAR T cells) that targets specific markers on acute myeloid leukemia cells. It aims to control the leukemia, but it also involves close monitoring because it is an early-phase study.
Shenzhen, GuangdongAges 2–75
Hear when a new Leukemia Acute Myeloid - AML trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for leukemia acute myeloid - aml?
- Yes. Clin2 currently lists 100 recruiting leukemia acute myeloid - aml studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a leukemia acute myeloid - aml trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a leukemia acute myeloid - aml trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.